Kadar hs-CRP pada Pasien Dispepsia dengan Infeksi Helicobacter pylori Dibandingkan dengan tanpa nfeksi Helicobacter pyorii
58
DAFTAR PUSTAKA
1. Siavoshi F, Malekzadah R, Daneshmand M, Ashktorab H.
Helicobacter Pylori endemic and gastric disease. Dig Dis Sci.
2005;50: 2075-80
2. Yoshiko I, Koji S, Kentaro T, et al. Significant association
between Helicobacter pylori infection and serum C-reactive
protein. International Journal of Medical Science. 2008, 5, 22429
3. Whincup PH, Mendall MA, Perry IJ, Strachan DP, Walker M.
Prospetive relations between Helicobacter pylori infection,
coronary heart disease, and stroke in middle aged men. Heart
1996;75:568-72
4. Kowalski M, Pawlik M, Konturek J W, Knturek SJ. Helicobacter
pylori in coronary artery disease. Journal of Physiology and
Pharmacology 2006, 57, supp 3, 101-11.
5. Liliana S, France G, et al. Serum Procalcitonin and C-Reactive
Protein Levels as Markers of Bacterial Infection: A Systemic
Review
and
Meta-analysis.
Clinical
Infection
Diseases.
2004;39:206-17
6. Settin D, Waldmann A, Strohle A, Hahn A. Association between
Helicobacter pyloti infection, C-reactive protein and status of B
vitamins. Advances in Medical Sciences. Vol 53(2) 2008, 205-13
Universitas Sumatera Utara
59
7. Al-Fawaeir S, Abu Zaid M. Serum levels of high sensitivity Creactive protein (hs-CRP) in Helicobacter pylori infected
patients. J Invest Biochem 2013;2(1):32-36
8. Oshima T, Ozono R, Yano Y, Oishi Y, Teragawa H, Higashi Y,
Yoshizumo M, Kambe M. Association of Helicobacter pylori
infection with systemic inflammation and endothelial dysfunction
in healthy male subjects. J Am. Coll Cardiol. 2005 Apr 19;4(8):
1219-22
9. Minocha A. Handbook of Digestive Disease. Black Incorporated.
2004; 19-21
10. Talley NJ, Holtman G. Approach to the patient with dyspepsia
and related functional gastrointestinal complaints. In: Yamada T,
et al, ed. Principles of Clinical Gastroenterology. Blackwell.
2008; 38-61
11. Hunt RH, Fallone C, Zanten SV, Sherman P, Flook N, Smaill F,
Thomson ABR. Etiology of Dyspepsia: Implications for Empirical
Therapy. Can J Gastroenterol 2002;16(9):635-41
12. Jones RH, Lipleard S. Prevalence of symptoms of dyspepsia in
the comunity. Br Med J 1989;298:30-2
13. Talley N, Zinsmeister A, Schexk C. Dyspepsia and dyspepsia
subgroups:
a
population-based
study.
Gastroenterology
1992;102:1259-68
14. Wang VS, Burakoff R, functional (non ulcer) Dyspepsia. In:
Greenberger MJ, ed. Current Diagnosis and Treatment
Universitas Sumatera Utara
60
Gastroenterology, hepatology & Endoscopy. McGraw-Hill, 2009.
189-99
15. Baker G, Fraser RJ, Young G. Subtypes of Functional
Dyspepsia. World Journal of Gastroenterology, 2007. May 7;
12(17) 2667-71
16. Wong J. Dyspepsia. In: Wong JLH, Murray I, Hussaini SH,
Dalton, HR, ed. Clinic Handbook Gastroenterology. 1st ed. Bios
2002;1-11
17. Lew E. Peptic Ulcer Disease. In: Greenberger NJ, Blumberg RS,
Burakoff
R,
ed.
Current
Diagnosis
&
Treatment
Gastroenterology, Hepatology & Endoscopy, McGraw-Hill. 2009.
175-83
18. Thompson AR, Barkun AN, Armstrong D, et al. The prevalence
of clinical significant endoscpic findings in primary care
patientswith uninvestigated dyspepsia: the Canadian Adult
Dyspepsia Empiric Treatment-Prompt Endoscopy (CADET-PE)
study. Aliment Pharmacol Ther: 2003;17:1481-91
19. Tepes B. Subgroups of Dyspepsia. In: Duvnjak M, ed.
Dyspepsia in Clinical Practice. Springer Science, 2011. 9-18
20. Soll AH. Consensus conference. Medical treatment of peptic
ulcer disease. Practical guidelines. Practical Parameters of the
American College of Gastroenterology. JAMA. 1996;275:622–9.
Universitas Sumatera Utara
61
21. Talley NJ, Silverstein MD, Agréus L, Nyrén O, Sonnenberg A,
Holtmann G. AGA technical review: evaluation of dyspepsia.
Gastroenterology. 1998;114:582–95.
22. Hallas J, Bytzer P. Screening for drug related dyspepsia: an
analysis of prescription symmetry. Eur J Gastroenterol Hepatol.
1998;10:27–32
23. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal
disorders. Gastroenterology. 2006;130:1466–79.
24. Tack J. Dyspepsia. In Feldman M, Friedman LS, Brandt LJ.
Sleisenger and Fordtran’s gastrointestinal and liver disease:
patophysiology/diagnosis management. 9th ed. Vol 1. Saunders
Elsevier, 2010. 183-95
25. Baker G, Fraser RJ, Young G. Subtypes of functional
dyspepsia. World J Gastroenterol 2006 May 7; 12(17): 26672671
26. Parsonnet J. Helicobacter pylori: the size of the problem. Gut
1998;43 (suppl 1):56-9
27. Dunn BE, Cohen H, Blaser MJ. Helicobacter Pylori. Clinical
Microbiology Reviews, vol. 10, no. 4 Oct. 1997, 720-41
28. Kusters JG, Van Vliet AHM, Kuipers EJ. Pathogenesis of
Helicobacter pylori Infection. Clinical Microbiology Reviews, July
2006;449-90
Universitas Sumatera Utara
62
29. Koskenpato J. Helicobacter pylori and Functional Dyspepsia.
Department of Medicine Tampere University Hospital, Finland.
Helsinki 2001
30. Parsonnet J. Helicobacter pylori: the size of the problem. Gut
1998;43 (suppl 1):56-9
31. Jenks PJ. Helicobacter spp. and Related Organisms in
Principles and Practice of Clinical Bacteriology 2nd ed. John
Wiley & Sons, Ltd 2006; 40:473-83
32. Redeen S. Chronic Gastritis Diagnosis, natural History and
consequences. Linkoping University Medical Dissertation.
33. Chiba N. Ulcer Disease and Helicobacter pylori. In: Mc Donald,
JW D, Burroughs AK, Feagan BG, ed. Evidence-based
Gastroenterology and Child Health, 2nd ed. Blackwell. 2004:
82-116
34. Fleming SL. Deadly Diseases and Epidemics Helicobacter
Pylori. Chelsea House Publishing. 2007.
35. Surbaum S, Michetti P. Medical Progress Helicobacter pylori
Infection. NEJM Oct 10, 2002, vol. 347, no. 15
36. Marshall BJ, Gilman RH. Helicobacter Pylori Infection. In:
Guerrant RL, Walker DH, Weller PE, ed. Tropical Infectious
Disease. Principles, Pathogens, & Practice. 2nd ed. Elsevier,
Churchill Livingstone, 2004: 300-5
Universitas Sumatera Utara
63
37. Rojas GC, Hiriart MM, Vidal YL. Helicobacter Pylori. Focus on
CagA and VacA Major Virulence Factors. Salud publica de
Mexico, 2004 vol. 46 No 6: 538-48
38. Glupzynski Y. Microbiological and serological diagnostic tests
for Helicobacter pylori. An overview. British Medical Bulletin.
1998; 54(no.1) 175-86
39. Soll AD, Graham DY. Approach to the patient with dyspepsia
and peptic ulcer disease. In: Yamada T, Alpers DH, kalloo AN,
ed. Principles of Clinical Gastroenterology. 1st ed. Wiley
Blackwell. 2008: 99-121
40. Andrews J, Marsden B, Brown D, et al. Comparison of three
stool antigen tests for Helicobacter pylori detection. J. Clin.
Athol. 2003; 56: 769-71
41. Thomas R. screening for Helicobacter pylori. Rev. Port. Clin.
Geral. 2006; 22: 585-9
42. Yi-huil,
Hong
G,
Peng-Bing
Z,et
al. Clinical
Value
of
Helicobacter pylori stool antigen test, immunocard STAT HpSA,
for detecting H. pylori infection. World J. Gastroenterology,
March 2004 voll10, no 6: 913-4
43. Velozzi EM, Guigliano ER. The Genus Helicobacter. In:
Goldman E, Greer LH, ed. Practical Handbook of Microbiology,
2 nd ed. Taylor & Francis 2009: 579-602
Universitas Sumatera Utara
64
44. Velozzi EM, Guigliano ER. The genus Helicobacter. In:
Goldman E, Greer LH, ed. Practical Handbook of Microbiology,
2nd ed. Taylor & Francis 2009: 579-602
45. Jialal I, Devaraj S. Modulation of Biomarkers of Inflammation. In:
Ballantyne CM, ed. Clinical Lipidology. A companion to
Braunwald’s Heart Disease, 1st ed. Saunders Elsevier 2009:
396-404
46. Rifai N. Analytic Issues for Clinical Use of C-Reactive Protein.
In: Morrow DA, ed. Cardiovascular biomarkers pathophysiology
and disease management. Humana press 2006: 229-34
47. Rifai N. Analytic Issues for Clinical Use of C-Reactive Protein.
In: Morrow DA, ed. Cardiovascular biomarkers pathophysiology
and disease management. Humana press 2006: 229-34
48. Farraj M, Salem N. C-reactive protein. In Blood cell – An
overview ofstudies in hematology.
Intech open science.
2012;89-100
49. Baiber AR, Recinos III A, Eledrisi MS. Vascular inflammation as
a cardiovascular risk factor. In: Runge MS, Patterson C, ed.
Principles of Molecular Cardiology. Humana press 2005: 577604
50. Lonn ME, Smieja M, Yusuf S. Emerging
approach in
cardiovascular prevention. In: Yusuf S, Cairns JA, Camm AJ, et
al, ed. Evidence-based Cardiology, 2nd ed: 219-30
Universitas Sumatera Utara
65
51. Rifai N. High sensitifity C-Reactive protein: a useful marker for
cardiovascular disease risk prediction and the metabolic
syndrome. Clinical chemistry 2005 . 51. No. 3: 504-5
52. Ridker PM, Hennekens CH, Buring JF, Rifai N. C-reactive
protein and other markers of inflammation in the prediction of
cardiovascular disease in women. NEJM March 23 2000; 342:
no. 12. 836-43
53. CRPHS, cobas, 2011. 6.V6 Englis
54. One step H.pylori Antigen rapid tsest in human fecal specimen.
SD Bioline H.pylori Ag
55. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum
procalcitonin and C-Reactive protein levels as marker of
bacterial infection: A systemic review and meta-analysis. CID
2004:39; 206-17
56. Andersen
LP,
Holck
S,
Janulaityte-Gunther
D,
et
al.
Inflammatory markers and interleukin in patients with functional
dyspepsia, with and without Helicobacter pylori infection. FEMS
Immunology and Medical Microbiology 44 (2005) 233–238
57. Suat S, Bekir K, Mustafa A, et al. Do procalcitonin and Creactive protein levels have a place in the diagnosis and followup of Helicobacter pylori infections? J Med Microbiol. 2004; 53:
639-44.
Universitas Sumatera Utara
DAFTAR PUSTAKA
1. Siavoshi F, Malekzadah R, Daneshmand M, Ashktorab H.
Helicobacter Pylori endemic and gastric disease. Dig Dis Sci.
2005;50: 2075-80
2. Yoshiko I, Koji S, Kentaro T, et al. Significant association
between Helicobacter pylori infection and serum C-reactive
protein. International Journal of Medical Science. 2008, 5, 22429
3. Whincup PH, Mendall MA, Perry IJ, Strachan DP, Walker M.
Prospetive relations between Helicobacter pylori infection,
coronary heart disease, and stroke in middle aged men. Heart
1996;75:568-72
4. Kowalski M, Pawlik M, Konturek J W, Knturek SJ. Helicobacter
pylori in coronary artery disease. Journal of Physiology and
Pharmacology 2006, 57, supp 3, 101-11.
5. Liliana S, France G, et al. Serum Procalcitonin and C-Reactive
Protein Levels as Markers of Bacterial Infection: A Systemic
Review
and
Meta-analysis.
Clinical
Infection
Diseases.
2004;39:206-17
6. Settin D, Waldmann A, Strohle A, Hahn A. Association between
Helicobacter pyloti infection, C-reactive protein and status of B
vitamins. Advances in Medical Sciences. Vol 53(2) 2008, 205-13
Universitas Sumatera Utara
59
7. Al-Fawaeir S, Abu Zaid M. Serum levels of high sensitivity Creactive protein (hs-CRP) in Helicobacter pylori infected
patients. J Invest Biochem 2013;2(1):32-36
8. Oshima T, Ozono R, Yano Y, Oishi Y, Teragawa H, Higashi Y,
Yoshizumo M, Kambe M. Association of Helicobacter pylori
infection with systemic inflammation and endothelial dysfunction
in healthy male subjects. J Am. Coll Cardiol. 2005 Apr 19;4(8):
1219-22
9. Minocha A. Handbook of Digestive Disease. Black Incorporated.
2004; 19-21
10. Talley NJ, Holtman G. Approach to the patient with dyspepsia
and related functional gastrointestinal complaints. In: Yamada T,
et al, ed. Principles of Clinical Gastroenterology. Blackwell.
2008; 38-61
11. Hunt RH, Fallone C, Zanten SV, Sherman P, Flook N, Smaill F,
Thomson ABR. Etiology of Dyspepsia: Implications for Empirical
Therapy. Can J Gastroenterol 2002;16(9):635-41
12. Jones RH, Lipleard S. Prevalence of symptoms of dyspepsia in
the comunity. Br Med J 1989;298:30-2
13. Talley N, Zinsmeister A, Schexk C. Dyspepsia and dyspepsia
subgroups:
a
population-based
study.
Gastroenterology
1992;102:1259-68
14. Wang VS, Burakoff R, functional (non ulcer) Dyspepsia. In:
Greenberger MJ, ed. Current Diagnosis and Treatment
Universitas Sumatera Utara
60
Gastroenterology, hepatology & Endoscopy. McGraw-Hill, 2009.
189-99
15. Baker G, Fraser RJ, Young G. Subtypes of Functional
Dyspepsia. World Journal of Gastroenterology, 2007. May 7;
12(17) 2667-71
16. Wong J. Dyspepsia. In: Wong JLH, Murray I, Hussaini SH,
Dalton, HR, ed. Clinic Handbook Gastroenterology. 1st ed. Bios
2002;1-11
17. Lew E. Peptic Ulcer Disease. In: Greenberger NJ, Blumberg RS,
Burakoff
R,
ed.
Current
Diagnosis
&
Treatment
Gastroenterology, Hepatology & Endoscopy, McGraw-Hill. 2009.
175-83
18. Thompson AR, Barkun AN, Armstrong D, et al. The prevalence
of clinical significant endoscpic findings in primary care
patientswith uninvestigated dyspepsia: the Canadian Adult
Dyspepsia Empiric Treatment-Prompt Endoscopy (CADET-PE)
study. Aliment Pharmacol Ther: 2003;17:1481-91
19. Tepes B. Subgroups of Dyspepsia. In: Duvnjak M, ed.
Dyspepsia in Clinical Practice. Springer Science, 2011. 9-18
20. Soll AH. Consensus conference. Medical treatment of peptic
ulcer disease. Practical guidelines. Practical Parameters of the
American College of Gastroenterology. JAMA. 1996;275:622–9.
Universitas Sumatera Utara
61
21. Talley NJ, Silverstein MD, Agréus L, Nyrén O, Sonnenberg A,
Holtmann G. AGA technical review: evaluation of dyspepsia.
Gastroenterology. 1998;114:582–95.
22. Hallas J, Bytzer P. Screening for drug related dyspepsia: an
analysis of prescription symmetry. Eur J Gastroenterol Hepatol.
1998;10:27–32
23. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal
disorders. Gastroenterology. 2006;130:1466–79.
24. Tack J. Dyspepsia. In Feldman M, Friedman LS, Brandt LJ.
Sleisenger and Fordtran’s gastrointestinal and liver disease:
patophysiology/diagnosis management. 9th ed. Vol 1. Saunders
Elsevier, 2010. 183-95
25. Baker G, Fraser RJ, Young G. Subtypes of functional
dyspepsia. World J Gastroenterol 2006 May 7; 12(17): 26672671
26. Parsonnet J. Helicobacter pylori: the size of the problem. Gut
1998;43 (suppl 1):56-9
27. Dunn BE, Cohen H, Blaser MJ. Helicobacter Pylori. Clinical
Microbiology Reviews, vol. 10, no. 4 Oct. 1997, 720-41
28. Kusters JG, Van Vliet AHM, Kuipers EJ. Pathogenesis of
Helicobacter pylori Infection. Clinical Microbiology Reviews, July
2006;449-90
Universitas Sumatera Utara
62
29. Koskenpato J. Helicobacter pylori and Functional Dyspepsia.
Department of Medicine Tampere University Hospital, Finland.
Helsinki 2001
30. Parsonnet J. Helicobacter pylori: the size of the problem. Gut
1998;43 (suppl 1):56-9
31. Jenks PJ. Helicobacter spp. and Related Organisms in
Principles and Practice of Clinical Bacteriology 2nd ed. John
Wiley & Sons, Ltd 2006; 40:473-83
32. Redeen S. Chronic Gastritis Diagnosis, natural History and
consequences. Linkoping University Medical Dissertation.
33. Chiba N. Ulcer Disease and Helicobacter pylori. In: Mc Donald,
JW D, Burroughs AK, Feagan BG, ed. Evidence-based
Gastroenterology and Child Health, 2nd ed. Blackwell. 2004:
82-116
34. Fleming SL. Deadly Diseases and Epidemics Helicobacter
Pylori. Chelsea House Publishing. 2007.
35. Surbaum S, Michetti P. Medical Progress Helicobacter pylori
Infection. NEJM Oct 10, 2002, vol. 347, no. 15
36. Marshall BJ, Gilman RH. Helicobacter Pylori Infection. In:
Guerrant RL, Walker DH, Weller PE, ed. Tropical Infectious
Disease. Principles, Pathogens, & Practice. 2nd ed. Elsevier,
Churchill Livingstone, 2004: 300-5
Universitas Sumatera Utara
63
37. Rojas GC, Hiriart MM, Vidal YL. Helicobacter Pylori. Focus on
CagA and VacA Major Virulence Factors. Salud publica de
Mexico, 2004 vol. 46 No 6: 538-48
38. Glupzynski Y. Microbiological and serological diagnostic tests
for Helicobacter pylori. An overview. British Medical Bulletin.
1998; 54(no.1) 175-86
39. Soll AD, Graham DY. Approach to the patient with dyspepsia
and peptic ulcer disease. In: Yamada T, Alpers DH, kalloo AN,
ed. Principles of Clinical Gastroenterology. 1st ed. Wiley
Blackwell. 2008: 99-121
40. Andrews J, Marsden B, Brown D, et al. Comparison of three
stool antigen tests for Helicobacter pylori detection. J. Clin.
Athol. 2003; 56: 769-71
41. Thomas R. screening for Helicobacter pylori. Rev. Port. Clin.
Geral. 2006; 22: 585-9
42. Yi-huil,
Hong
G,
Peng-Bing
Z,et
al. Clinical
Value
of
Helicobacter pylori stool antigen test, immunocard STAT HpSA,
for detecting H. pylori infection. World J. Gastroenterology,
March 2004 voll10, no 6: 913-4
43. Velozzi EM, Guigliano ER. The Genus Helicobacter. In:
Goldman E, Greer LH, ed. Practical Handbook of Microbiology,
2 nd ed. Taylor & Francis 2009: 579-602
Universitas Sumatera Utara
64
44. Velozzi EM, Guigliano ER. The genus Helicobacter. In:
Goldman E, Greer LH, ed. Practical Handbook of Microbiology,
2nd ed. Taylor & Francis 2009: 579-602
45. Jialal I, Devaraj S. Modulation of Biomarkers of Inflammation. In:
Ballantyne CM, ed. Clinical Lipidology. A companion to
Braunwald’s Heart Disease, 1st ed. Saunders Elsevier 2009:
396-404
46. Rifai N. Analytic Issues for Clinical Use of C-Reactive Protein.
In: Morrow DA, ed. Cardiovascular biomarkers pathophysiology
and disease management. Humana press 2006: 229-34
47. Rifai N. Analytic Issues for Clinical Use of C-Reactive Protein.
In: Morrow DA, ed. Cardiovascular biomarkers pathophysiology
and disease management. Humana press 2006: 229-34
48. Farraj M, Salem N. C-reactive protein. In Blood cell – An
overview ofstudies in hematology.
Intech open science.
2012;89-100
49. Baiber AR, Recinos III A, Eledrisi MS. Vascular inflammation as
a cardiovascular risk factor. In: Runge MS, Patterson C, ed.
Principles of Molecular Cardiology. Humana press 2005: 577604
50. Lonn ME, Smieja M, Yusuf S. Emerging
approach in
cardiovascular prevention. In: Yusuf S, Cairns JA, Camm AJ, et
al, ed. Evidence-based Cardiology, 2nd ed: 219-30
Universitas Sumatera Utara
65
51. Rifai N. High sensitifity C-Reactive protein: a useful marker for
cardiovascular disease risk prediction and the metabolic
syndrome. Clinical chemistry 2005 . 51. No. 3: 504-5
52. Ridker PM, Hennekens CH, Buring JF, Rifai N. C-reactive
protein and other markers of inflammation in the prediction of
cardiovascular disease in women. NEJM March 23 2000; 342:
no. 12. 836-43
53. CRPHS, cobas, 2011. 6.V6 Englis
54. One step H.pylori Antigen rapid tsest in human fecal specimen.
SD Bioline H.pylori Ag
55. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum
procalcitonin and C-Reactive protein levels as marker of
bacterial infection: A systemic review and meta-analysis. CID
2004:39; 206-17
56. Andersen
LP,
Holck
S,
Janulaityte-Gunther
D,
et
al.
Inflammatory markers and interleukin in patients with functional
dyspepsia, with and without Helicobacter pylori infection. FEMS
Immunology and Medical Microbiology 44 (2005) 233–238
57. Suat S, Bekir K, Mustafa A, et al. Do procalcitonin and Creactive protein levels have a place in the diagnosis and followup of Helicobacter pylori infections? J Med Microbiol. 2004; 53:
639-44.
Universitas Sumatera Utara